Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial

Abstract : Purpose Report the efficacy and safety of pasireotide sc in patients with Cushing's disease during an open-ended, open-label extension to a randomized, double-blind, 12-month, Phase III study. Methods 162 patients entered the core study. 58 patients who had mean UFC B ULN at month 12 or were bene-fiting clinically from pasireotide entered the extension. Patients received the same dose of pasireotide as at the end of the core study (300–1,200 lg bid). Dose titration was permitted according to efficacy or drug-related adverse events. Results 40 patients completed 24 months' treatment. Of the patients who entered the extension, 50.0 % (29/58) and 34.5 % (20/58) had controlled UFC (UFC B ULN) at months 12 and 24, respectively. The mean percentage decrease in UFC was 57.3 % (95 % CI 40.7–73.9; n = 52) and 62.1 % (50.8–73.5; n = 33) after 12 and 24 months' treatment, respectively. Improvements in clinical signs of Cushing's disease were sustained up to month 24. The most frequent drug-related adverse events in patients who received C1 dose of pasireotide (n = 162) from core baseline until the 24-month cut-off were diarrhea (55.6 %), nausea (48.1 %), hyperglycemia (38.9 %), and cholelithi-asis (31.5 %). No new safety issues were identified during the extension. Conclusions Reductions in mean UFC and improvements in clinical signs of Cushing's disease were maintained over 24 months of pasireotide treatment. The safety profile of pasireotide is typical for a somatostatin analogue, except for the frequency and degree of hyperglycemia; patients should be monitored for changes in glucose homeostasis. Pasireotide represents the first approved pituitary-targeted treatment for patients with Cushing's disease.-1) contains supplementary material, which is available to authorized users.
Type de document :
Article dans une revue
Pituitary, Springer Verlag, 2014, pp.25537481. 〈10.1007/s11102-014-0618-1〉
Liste complète des métadonnées

Littérature citée [16 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01103399
Contributeur : Mireille Bos <>
Soumis le : mercredi 14 janvier 2015 - 16:18:06
Dernière modification le : jeudi 14 juin 2018 - 10:54:03
Document(s) archivé(s) le : mercredi 15 avril 2015 - 11:30:53

Fichier

Pituitary 2014 art.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Jochen Schopohl, Feng Gu, Robert Rubens, Luc Van Gaal, Bertherat Jerome, et al.. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial. Pituitary, Springer Verlag, 2014, pp.25537481. 〈10.1007/s11102-014-0618-1〉. 〈inserm-01103399〉

Partager

Métriques

Consultations de la notice

98

Téléchargements de fichiers

92